FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0	287			
Estimated average	burden				
nours per response	e	0.5			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person * MALFROY-CAMINE BERNARD				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director Officer (give title below) Other (specify below)							
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 07/10/2018													
(Street) WALTHAM, MA 02452			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person									
(City)	(State)	(Zip)	Т	able I -	Non-	Deri	vative S	ecurities	s Acqu	ired, Disp	osed of, or l	Beneficially	Owned			
1.Title of S (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Yea	(Instr			(A) or I	rities Acc Disposed , 4 and 5	of (D)	Beneficia Reported	Beneficially Owned Following Reported Transaction(s)		Reported Transaction(s) Form: Direct		d Following Ownership of Indicates on(s) Form: Beneficially Ownership or Indirect (Instru	
					Co	de	V	Amoun	· · /	Price				(Instr. 4)			
Common	Stock		07/10/2018		A			50,000 (1)) A	\$ 0	61,525			D			
Reminder:	Report on a s	separate line fo		Derivative Securi	ties Acq	P c th	Personta he fo	ons who ained in orm dis	o respo this fo plays a f, or Be	rm ar curre neficia	e not requently valid	OMB con	formation spond unle trol numbe	ess	1474 (9-02)		
Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/	n 3A. Deemed Execution Da any	te, if Transaction Code Year) (Instr. 8)	5.	r (a) (ive ies ed ed ed s, (5)	6. Da and E (Mon	tte Exerc Expiratio hth/Day/\frac{1}{2}	isable n Date Year)	7. T Am Und Sec (Ins 4)	Fitle and ount of derlying urities str. 3 and		9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Owners Form o Derivat Security Direct (or Indir	Benefic Owners (Instr. 4		
				Code V	(A) (F	Date Exerc		Expiratio Date	Titl	e Number of Shares						

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MALFROY-CAMINE BERNARD C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452	X					

Signatures

/s/ Robert A. Petitt, Attorney-in-Fact (Signed under power of attorney on behalf of Reporting Person)	07/12/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to all of the shares on July 10, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.